Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
Avatar

How I Treat AML in 2020: Is Addition of Azacitidine to Venetoclax/Placebo Viable? How Effective Is Magrolimab + AZA Combo?

By 7th Eurasian Hematology Oncology Summit FEATURING Farhad Ravandi
By 7th Eurasian Hematology Oncology Summit FEATURING Farhad Ravandi
0 views
September 30, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Leukemia
07:30
7th Eurasian Hematology Oncology Summit

Rational Drug Use for Hematologic Malignancies: How Do We Define It?…

Feat. M. Yilmaz
14:53
7th Eurasian Hematology Oncology Summit

2020 Updates on MRD in Adult ALL: How Does MRD Help With the Assessm…

Feat. F. Ravandi
12:22
7th Eurasian Hematology Oncology Summit

2020 Updates on Frontline AML: Does Midostaurin+Chemo Reduce the Ris…

Feat. G. Martinelli
23:15
7th Eurasian Hematology Oncology Summit

2020 Frontline CML Update: Comparing TKI Inhibitors, Achieving TFR i…

Feat. G. Saglio
15:13
7th Eurasian Hematology Oncology Summit

How I Treat Frontline CML in 2020: Does Imatinib Improve Long-Term S…

Feat. H. Kantarjian
14:55
7th Eurasian Hematology Oncology Summit

How I Treat Frontline ALL in 2020: Does Ph-Like Disease Have a Highe…

Feat. H. Kantarjian
17:21
7th Eurasian Hematology Oncology Summit

2020 Update on MRD in AML: Does Decitabine Prolong RFS/OS in Newly D…

Feat. F. Ravandi
14:41
7th Eurasian Hematology Oncology Summit

How I Treat AML in 2020: Is Addition of Azacitidine to Venetoclax/Pl…

Feat. F. Ravandi
21:52
7th Eurasian Hematology Oncology Summit

2020 Efficacy Data on Targeted Therapies in CLL: Do We Need to Combi…

Feat. P. Panayiotidis
18:04
7th Eurasian Hematology Oncology Summit

How I Treat CLL in 2020: How Do Ibrutinib/Rituximab & Venetoclax…

Feat. R. Foa